Patents by Inventor Michael Fung
Michael Fung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240130719Abstract: Delivery devices configured to deliver therapeutic and visualization devices to a surgical site are disclosed. An example delivery device may include a proximally disposed handle; a shaft extending distally from the handle, the shaft including a therapeutic device lumen configured to deliver a working end of a therapeutic device therethrough, a first portion of the shaft being steerable; and a space-making element disposed proximate a distal end portion of the shaft and configured to separate biological tissues to create or expand a working space. At least a portion of the space-making element may be reconfigurable between a retracted configuration and an expanded configuration.Type: ApplicationFiled: March 14, 2022Publication date: April 25, 2024Applicant: AtriCure, Inc.Inventors: Michael J. Banchieri, Ara M. Stephanian, Jeremy D. Dando, Feng Liu, Greg Fung, Jean-Pierre Dueri
-
Publication number: 20240094195Abstract: The present invention relates to a method for assessing respiratory viral infections, the method includes preparing one or more precision-cut human bronchial tissues; exposing a cilia-rich epithelium within the precision-cut human bronchial tissues to establish an ex vivo model of human bronchus for viral infections; assessing infectivity, tropism, and pathogenesis of one or more respiratory viruses in the ex vivo model; and providing a semi-quantitative and normalized approach to supplement data from the ex vivo model of human bronchus for pandemic risk assessment of the one or more respiratory viruses. The present invention involves micro-dissection of bronchial tissues to expose the cilia-rich epithelium for ex vivo virus infection, along with a semi-quantitative approach for analyzing virus tropism and replication competence.Type: ApplicationFiled: September 14, 2023Publication date: March 21, 2024Inventors: Chi Wai Michael CHAN, Pui Yan HUI, John Malcolm NICHOLLS, Hiu Ha CHING, Hau Yin Kevin FUNG
-
Publication number: 20160264682Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: March 21, 2016Publication date: September 15, 2016Inventors: Michael Fung, William N.C. Sun, Cecily R. Y. Sun
-
Publication number: 20160200805Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: ApplicationFiled: March 22, 2016Publication date: July 14, 2016Inventors: Michael Fung, Mason Lu, William N.C. Sun, Cecily R.Y. Sun
-
Publication number: 20150086572Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: ApplicationFiled: November 24, 2014Publication date: March 26, 2015Inventors: Michael Fung, Meisheng Lu, William N.C. Sun, Cecily R.Y. Sun
-
Publication number: 20150010569Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: May 29, 2014Publication date: January 8, 2015Inventors: Michael Fung, William N.C. Sun, Cecily R. Y. Sun
-
Patent number: 8907072Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: February 5, 2013Date of Patent: December 9, 2014Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8765131Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: February 5, 2013Date of Patent: July 1, 2014Assignee: Genentech, Inc.Inventors: Michael Fung, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20130230522Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: ApplicationFiled: February 5, 2013Publication date: September 5, 2013Applicant: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8372404Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: May 29, 2012Date of Patent: February 12, 2013Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20120301483Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: ApplicationFiled: May 29, 2012Publication date: November 29, 2012Applicant: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8206716Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: January 24, 2008Date of Patent: June 26, 2012Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20110200604Abstract: The present invention relates to novel peptide epitopes derived from the CH3 domain of IgE which are recognized by high affinity antibodies that specifically bind IgE. These novel peptides may be used for both active immunization of a subject by administering these peptides to generate high affinity antibodies in a subject, as well as for generating high affinity anti-IgE antibodies in non-human hosts that specifically bind to these regions of IgE for passive immunization of a subject.Type: ApplicationFiled: September 10, 2010Publication date: August 18, 2011Inventors: Sanjaya Singh, Danyang Huang, Sek Chung Michael Fung
-
Publication number: 20110180096Abstract: A curling iron has a heatable barrel defining a lengthwise axis of the curling iron, a handle assembly having a grip, and a rotation mechanism coupled to a proximal end of the barrel and part of the handle assembly. The rotation mechanism permits rotation of at least part of the handle assembly relative to the barrel about the lengthwise axis of the curling iron between two or more different rotational orientations.Type: ApplicationFiled: December 22, 2010Publication date: July 28, 2011Applicant: Goody Products, Inc.Inventors: Joe Palermo, Stan Chudzik, Herbert Lun, Dick Wong, Fredrick Ho, Michael Fung, Raymond Poon
-
Patent number: 7432356Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: August 17, 2002Date of Patent: October 7, 2008Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20080118508Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: ApplicationFiled: January 24, 2008Publication date: May 22, 2008Inventors: Michael Fung, Meisheng Lu, William Sun, Cecily Sun
-
Publication number: 20060240020Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: June 29, 2006Publication date: October 26, 2006Inventors: Michael Fung, William Sun, Cecily Sun
-
Publication number: 20050232920Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: May 27, 2005Publication date: October 20, 2005Inventors: Michael Fung, William Sun, Cecily Sun
-
Publication number: 20050196394Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: ApplicationFiled: May 24, 2005Publication date: September 8, 2005Applicant: TANOX,INC.Inventor: Michael Fung
-
Publication number: 20030129187Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: ApplicationFiled: August 17, 2002Publication date: July 10, 2003Applicant: Tanox, Inc.Inventors: Michael Fung, Meisheng Lu, William N.C. Sun, Cecily R.Y. Sun